Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Bicara Therapeutics Inc (NASDAQ: BCAX) closed at $18.0 in the last session, down -0.94% from day before closing price of $18.17. In other words, the price has decreased by -$0.94 from its previous closing price. On the day, 0.51 million shares were traded. BCAX stock price reached its highest trading level at $18.38 during the session, while it also had its lowest trading level at $17.67.
Ratios:
We take a closer look at BCAX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 25.80 and its Current Ratio is at 25.80. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On May 23, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $8.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $8.Wells Fargo initiated its Underweight rating on April 17, 2025, with a $8 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 07 ’25 when Hyep Ivan sold 18,244 shares for $18.22 per share. The transaction valued at 332,386 led to the insider holds 145,355 shares of the business.
Hyep Ivan sold 6,514 shares of BCAX for $118,356 on Oct 06 ’25. The Chief Financial Officer now owns 145,355 shares after completing the transaction at $18.17 per share. On Oct 08 ’25, another insider, Hyep Ivan, who serves as the Chief Financial Officer of the company, sold 5,627 shares for $18.21 each. As a result, the insider received 102,456 and left with 145,355 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAX now has a Market Capitalization of 992308736 and an Enterprise Value of 547763136.
Stock Price History:
The Beta on a monthly basis for BCAX is -0.88, which has changed by -0.052631557 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, BCAX has reached a high of $28.09, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is 47.42%, while the 200-Day Moving Average is calculated to be 43.97%.
Shares Statistics:
According to the various share statistics, BCAX traded on average about 399.35K shares per day over the past 3-months and 812540 shares per day over the past 10 days. A total of 54.56M shares are outstanding, with a floating share count of 30.96M. Insiders hold about 43.30% of the company’s shares, while institutions hold 64.11% stake in the company. Shares short for BCAX as of 1757894400 were 5669220 with a Short Ratio of 14.20, compared to 1755216000 on 5460303. Therefore, it implies a Short% of Shares Outstanding of 5669220 and a Short% of Float of 16.259999999999998.
Earnings Estimates
. The current market rating for Bicara Therapeutics Inc (BCAX) reflects the collective analysis of 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.37 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.91 and -$2.43 for the fiscal current year, implying an average EPS of -$2.22. EPS for the following year is -$2.45, with 8.0 analysts recommending between -$1.88 and -$3.01.
